Volume 12, Number 10—October 2006
Research
Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children
Lisa A. Prosser*†
, Carolyn Buxton Bridges‡, Timothy M. Uyeki‡, Virginia L. Hinrichsen*†, Martin I. Meltzer‡, Noelle-Angelique M. Molinari‡, Benjamin Schwartz‡, William W. Thompson‡, Keiji Fukuda‡, and Tracy A. Lieu*†§
, Carolyn Buxton Bridges‡, Timothy M. Uyeki‡, Virginia L. Hinrichsen*†, Martin I. Meltzer‡, Noelle-Angelique M. Molinari‡, Benjamin Schwartz‡, William W. Thompson‡, Keiji Fukuda‡, and Tracy A. Lieu*†§
Table 5
Incremental cost-effectiveness ratios for use of inactivated and live attenuated influenza vaccination in varying age and risk groups compared to no vaccination, mean (2.5% and 97.5% bootstrapped percentiles)*
| Age group | Using inactivated influenza vaccine | Using live, attenuated influenza vaccine† | ||
|---|---|---|---|---|
| Children not at high risk | Children at high risk | Children not at high risk | ||
| $ per influenza episode averted‡ | ||||
| 6–23 mo | 340 (CS–4,690) | CS (CS–4,090) | 240 (CS–3,890) | |
| 2 y | 400 (CS–3,990) | CS (CS–3,620) | 330 (CS–3,340) | |
| 3–4 y | 440 (10–3,590) | 20 (CS–3,410) | 440 (CS–3,170) | |
| 5–11 y | 800 (180–5,850) | 210 (CS–5,560) | 720 (170–5,290) | |
| 12–17 y | 1,070 (250–7,780) | 310 (CS–7,360) | 980 (240–7,070) | |
| $ per hospitalization averted‡ | ||||
| 6-23 mo | 19,000 (CS–350,000) | CS (CS–132,000) | 14,000 (CS–287,000) | |
| 2 y | 37,000 (CS–633,000) | CS (CS–232,000) | 30,000 (CS–522,000) | |
| 3–4 y | 84,000 (1,000–2,587,000) | 1,000 (CS–750,000) | 74,000 (CS–2,227,000) | |
| 5–11 y | 202,000 (38,000–1,929,000) | 9,000 (CS–310,000) | 184,000 (35,000–1,629,000) | |
| 12–17 y | 206,000 (43,000–1,768,000) | 10,000 (CS–304,000) | 188,000 (40,000–1,575,000) | |
| $ per death averted‡ | ||||
| 6–23 mo | 22 m (CS–1,109 m) | CS (CS–342 m) | 16 m (CS–880 m) | |
| 2 y | 42 m (CS–1,762 m) | CS (CS–591 m) | 34 m (CS–1,435 m) | |
| 3–4 y | 98 m (1 m–6,840 m) | 1 m (CS–1,873 m) | 86 m (CS;5,991 m) | |
| 5–11 y | 234 m (32 m–5,993 m) | 10 m (CS–876 m) | 212 m (32 m–5,331 m) | |
| 12–17 y | 238 m (37 m–5,607 m) | 12 m (CS–892 m) | 217 m (34 m–5,007 m) | |
| $ per quality-adjusted life-year saved | ||||
| 6–23 mo | 12,000 (CS–208,000) | CS (CS–85,000) | 9,000 (CS–167,000) | |
| 2 y | 18,000 (CS–217,000) | CS (CS–100,000) | 15,000 (CS–180,000) | |
| 3–4 y | 28,000 (1,000–290,000) | 1,000 (CS–130,000) | 25,000 (CS–236,000) | |
| 5–11 y | 79,000 (15,000–682,000) | 7,000 (CS–260,000) | 72,000 (14,000–592,000) | |
| 12–17 y | 119,000 (24,000–1,040,000) | 10,000 (CS–367,000) | 109,000 (22,000–888,000)
*CS, cost savings; m, million. | |
*CS, cost savings; m, million.
†Numerator does not include productivity losses.
‡Italics indicate that live, attenuated influenza vaccine is not licensed for children <5 y.
Page created: November 09, 2011
Page updated: November 09, 2011
Page reviewed: November 09, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.